Increasing evidence suggests that unsatisfactory therapeutic outcomes and the poor prognosis associated with pancreatic cancer are related to aberrantly activated signaling pathways, including NF-κB signaling [5, 6]. Here, NFKB1 is linked to familial pancreatic carcinoma.